On Jan 27, 2022 Ractigen Therapeutics closed a Series A round and raised $30,000,000 from China Singapore Suzhou Industrial Park Ventures, Eisai, LC Ventures, SDIC Venture Capital, Xianghe Capital, featuring lead investors SDIC Venture Capital.

About the company: Ractigen Therapeutics is located at China, Asia.
“Ractigen is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.”

Company website: http://www.ractigen.com